Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge by Major, Diane et al.
Intranasal vaccination with a plant-derived H5 HA
vaccine protects mice and ferrets against highly
pathogenic avian inﬂuenza virus challenge
Diane Major1,y, Jessica A Chichester2,y, Rishi D Pathirana3,4,5, Kate Guilfoyle1, Yoko Shoji2, Carlos A Guzman6, Vidadi Yusibov2,
and Rebecca J Cox3,4,5,*
1National Institute for Biological Standards and Control; Medicines and Healthcare Products Regulatory Agency; Potters Bar, UK; 2Fraunhofer USA Center for Molecular
Biotechnology; Newark, DE USA; 3Inﬂuenza Center; Department of Clinical Science; University of Bergen; Bergen, Norway; 4Department of Research & Development;
Haukeland University Hospital; Bergen, Norway; 5K.G. Jebsen Center for Inﬂuenza Vaccine Research; University of Bergen; Bergen, Norway; 6Department of Vaccinology and
Applied Microbiology; Helmholtz Center for Infection Research; Braunschweig, Germany
yThese authors equally contributed to this work.
Keywords: adjuvant, c-di-GMP, influenza H5N1, intranasal vaccination, ferret infection model, mice, plant vaccine
Abbreviations: c-di-GMP, (30, 50)-cyclic dimeric guanylic acid
Highly pathogenic avian inﬂuenza H5N1 infection remains a public health threat and vaccination is the best measure of
limiting the impact of a potential pandemic. Mucosal vaccines have the advantage of eliciting immune responses at the
site of viral entry, thereby preventing infection as well as further viral transmission. In this study, we assessed the protective
efﬁcacy of hemagglutinin (HA) from the A/Indonesia/05/05 (H5N1) strain of inﬂuenza virus that was produced by transient
expression in plants. The plant-derived vaccine, in combination with the mucosal adjuvant (30,50)-cyclic dimeric guanylic
acid (c-di-GMP) was used for intranasal immunization of mice and ferrets, before challenge with a lethal dose of the A/
Indonesia/05/05 (H5N1) virus. Mice vaccinated with 15 mg or 5 mg of adjuvanted HA survived the viral challenge, while all
control mice died within 10 d of challenge. Vaccinated animals elicited serum hemagglutination inhibition, IgG and IgA
antibody titers. In the ferret challenge study, all animals vaccinated with the adjuvanted plant vaccine survived the lethal
viral challenge, while 50% of the control animals died. In both the mouse and ferret models, the vaccinated animals were
better protected from weight loss and body temperature changes associated with H5N1 infection compared with the non-
vaccinated controls. Furthermore, the systemic spread of the virus was lower in the vaccinated animals compared with the
controls. Results presented here suggest that the plant-produced HA-based inﬂuenza vaccine adjuvanted with c-di-GMP is
a promising vaccine/adjuvant combination for the development of new mucosal inﬂuenza vaccines.
Introduction
The highly pathogenic influenza (HPAI) virus subtype H5N1
continues to be a serious public health risk. Human cases have
recently been reported in Cambodia, Vietnam, Egypt, Indonesia
and elsewhere with a case fatality rate exceeding 60%.1 HPAI
viruses have not acquired transmissibility in humans, however
reassortant viruses containing HA from avian H5N1 and gene
segments from human H1N1 strains have been shown to effi-
ciently transmit in ferrets2 and guinea pigs3 by exchange of respi-
ratory droplets. Furthermore, Herfst et al.4 reported that the A/
Indonesia/05/05 (H5N1) virus can acquire mutations during pas-
sage and become transmissible by aerosol or respiratory droplets
in ferrets. Humans do not have pre-existing immunity to
influenza viruses with H5 HA, therefore if a HPAI virus acquires
transmissibility in humans, it would most likely cause a pandemic.
Vaccination is the best available measure of limiting the
impact of an influenza pandemic. Ideally, a candidate pandemic
influenza vaccine should be easy to administer, elicit strong
mucosal and systemic immune responses, and provide broad,
long-lasting immunity. Transient plant expression systems are a
rapid, cost effective and easily scalable new strategy for influenza
vaccine production to overcome the bottleneck in vaccine supply
during a pandemic.5 This is especially important in the event of
an influenza pandemic of an avian origin, as the HPAI virus kills
chick embryos and hens’ eggs that are used to produce most com-
mercial influenza vaccines. Furthermore, a needle-free intranasal
(IN) influenza vaccine is an attractive approach providing
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immunity at the portal of virus entry and overcoming the prob-
lems of limited healthcare providers. An earlier study reported
that IN vaccination with an Escherichia coli heat-labile toxin (LT)
adjuvanted influenza virosomes increase the risk of Bell’s palsy.6
However it was later discovered that this association was probably
due to the adjuvant, as another LT-adjuvanted IN vaccine (not
influenza) was also associated with Bell’s palsy.7
The bacterial c-di-GMP is an intracellular signaling molecule
that acts as a danger signal for eukaryotic cells (for a review see
ref.8) and several studies have identified its potential as an adju-
vant for mucosal and systemic vaccination.9-12 We have previ-
ously demonstrated immunostimulatory properties of c-di-GMP
when used as a mucosal influenza vaccine adjuvant in mice.11,12
IN or sublingual administration of c-di-GMP adjuvanted influ-
enza vaccines was shown to induce strong homologous and cross
reactive mucosal and systemic humoral immune responses, with
a balanced Th1/Th2 profile and high frequencies of multifunc-
tional Th1 CD4C T cells producing interferon-g (IFN- g),
tumor necrosis factor-a (TNF- a) and interleukin-2 (IL-2).
The current study investigated the ability of a c-di-GMP adju-
vanted, plant-derived H5 HA antigen to protect against a lethal
H5N1 influenza virus challenge in the murine and ferret models
of infection. We found that the IN administered c-di-GMP adju-
vanted vaccine provided protective immunity in both mice and
ferrets, therefore it is a promising mucosal vaccine formulation
for pre-pandemic influenza vaccine development.
Results
Immunogenicity and protective efficacy of H5 vaccine
in mice
Mouse immunogenicity study
To assess the immunogenicity of the plant-derived H5 HA vac-
cine adjuvanted with c-di-GMP, mice were immunized IN in a
prime boost regimen with 15, 5 or 1.5 mg of HA formulated with
5 mg cd-i-GMP or with 5 mg cd-i-GMP/PBS (control). Post-vac-
cination serum IgG responses were examined by ELISA. In all 3
HA-vaccinated groups, the IgG levels at day 21 were comparable
to pre-vaccination levels (day 0), but were significantly greater (P
< 0.05) following the 2nd vaccine dose (days 28, 35 and 42;
Fig. 1A). No increase in the serum IgG response was observed in
control mice on any of the days tested. The serum IgA response
was examined pre vaccination and 35 d post vaccination
(Fig. 1B). In all 3 HA-vaccinated groups, the IgA response was
significantly higher at day 35 compared with the pre-vaccination
levels (day 0), but no increase was detected in the control mice.
The IgA response was not significantly different at day 35 between
groups that received the 15, 5 or 1.5 mg HA vaccine dose.
Murine challenge study
To evaluate the protective efficacy of the vaccine, mice
received 2 IN doses (21 d apart) of vaccine at 15, 5 or 1.5 mg
HA formulated with 5 mg cdi-GMP or with 5 mg cdi-GMP/
PBS (controls) and were challenged with HPAI A/Indonesia/05/
05 (H5N1) on study day 42. HI assays were conducted with
Figure 1. HA-speciﬁc serum IgG (A) and IgA (B) responses in mice in the
immunogenicity study. Groups of 6 mice were immunized twice (21 day
interval) intranasally with plant derived H1N1 vaccine at 15, 5 or 1.5 mg
HA in combination with 5 mg of c-di-GMP or with PBS plus 5 mg cdi-GMP
(control). Blood samples were collected at days 0, 21, 28, 35 and 42 and
serum IgG and IgA levels were analyzed by ELISA. * D signiﬁcantly (P <
0.05) different from Day 0 titers.
Figure 2. Serum HI antibody response in mice before challenge with the
A/Indonesia/05/2005 (H5N1) virus. Groups of 16 mice were immunized
twice (21 day interval) intranasally with plant derived vaccine at 15, 5 or
1.5 mg HA in combination with 5 mg of c-di-GMP or with PBS plus 5 mg
cdi-GMP (control). Blood samples were collected pre-vaccination (Day
¡1) and at 20, 32, and 41 days post vaccination. The data show HI
responses of each individual mouse and the horizontal lines represent
geometric mean titers § 95% conﬁdence interval. The dotted line repre-
sents an HI titer of 40.
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serum collected pre-vaccination (Day ¡1) and at days 20, 32 and
41 post-vaccination (1 day before virus challenge, Fig. 2). No HI
response was detected pre-vaccination or after the first immuniza-
tion (day 20). After the second dose (days 32 and 41), the highest
HI titers were observed in the 15 mg HA group, with lower HI
titers detected in the 5 and 1.5 mg HA groups. An HI titer of
40 is considered protective against seasonal influenza strains in
man.13 As shown in Figure 2, at 32 and 41 days post-vaccina-
tion, 7 and 5 mice, respectively from the 15 mg HA vaccine
group had HI titers 40. In the 5 mg HA vaccine group, 6 mice
had HI titers 40 at 32 days after vaccination. No animals in
the 1.5 mg HA vaccine or in the control group had HI titers 40
after the second vaccine dose.
After viral challenge, 3 mice from each group were selected at
days 3 (day 45) and 5 (day 47) post-challenge to test for the pres-
ence of virus in the upper (nasal turbinates, Fig. 3A) and lower
(lung tissue, Fig. 3B) respiratory tract. Viral loads in the nasal
turbinates collected on both days were at or slightly above the
detection limit of 102.5 tissue culture infectious dose (TCID)50/
mL and were comparable across the 3 HA-vaccinated groups and
the control animals. The limit of detection for all lung tissues
was 101.5 TCID50/mL. The highest viral loads were detected in
the control group on both days 45 and 47. Three days post viral
challenge (day 45), mice vaccinated with 15 mg or 5 mg of HA
had no detectable virus in the lungs. In contrast, mice vaccinated
with 1.5 mg HA and control groups were positive for viral load
with group mean titers of 105 and 107.3 TCID50/mL, respec-
tively. Five days post challenge (day 47), a dose response was
observed with the group mean titers decreasing with an increas-
ing vaccine dose with titers of 102.9, 103.8, 104.4 and 105.5
TCID50/mL for 15, 5, 1.5 mg HA and control groups,
respectively.
Figure 3. Virus titers in the upper (nasal turbinates, A) and lower (lungs,
B) respiratory tract after challenge with the A/Indonesia/05/2005 (H5N1)
virus. Groups of 16 mice were immunized twice (21 day interval) intrana-
sally with plant derived vaccine at 15, 5 or 1.5 mg HA in combination
with 5 mg c-di-GMP or with 5 mg c-di-GMP/PBS (control). Mice were chal-
lenged by intranasal administration of highly pathogenic avian Inﬂuenza
A/Indonesia/05/2005 (H5N1) on day 42. Groups of 3 mice were eutha-
nized at days 3 (Day 45) and 5 (Day 47) post-challenge to examine for
the presence of virus in the upper (nasal turbinates, A) and lower (lungs,
B) respiratory tract. The limit of detection was 102.5 TCID50/mL for nasal
turbinates and 101.5 TCID50/mL for lung tissue.
Figure 4. Changes in body weight (A) and mortality (B) of vaccinated
mice after the A/Indonesia/05/2005 (H5N1) virus challenge. Groups of 16
mice were immunized twice (21 day interval) intranasally with the adju-
vanted vaccine at a HA content of 15, 5 or 1.5 mg or with 5 mg c-di-
GMP/PBS (control). Mice were challenged by intranasal administration of
highly pathogenic avian Inﬂuenza A/Indonesia/05/2005 (H5N1) on day
42. (A); Body weights were obtained daily for 2 weeks post-challenge
(days 0-14). The weight of the animals as measured on the day of viral
challenge (day 0) was used as the baseline weight to determine changes
in body weight post viral challenge. (B); The survival rate (percentage) of
mice was examined daily for 2 weeks post virus challenge.
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All animals were monitored for body weight and clinical signs
of disease on days 0, 7, 14, 21, 28, 35, 38 and 42 pre-challenge
(data not shown) and daily post-challenge for 2 weeks (Fig. 4).
The mean body weights in the 15 mg vaccine group remained sta-
ble until the scheduled euthanasia on day 14 post-challenge
(Fig. 4A). Mice vaccinated with 5 mg HA showed a temporary
loss of body weight between days 3 to 5 before they regained
weight between days 6 and 14 post-challenge (Fig. 4A). All ani-
mals vaccinated with either 15 or 5 mg HA survived viral chal-
lenge to the scheduled euthanasia on day 14 (Fig. 4B). Mice
vaccinated with 1.5 mg of HA lost weight between days 2 to 6
and then regained weight with minor fluctuations between days 7
and 14, however, only 80% of animals in this low dose group sur-
vived the virus challenge. In the control group, the mean body
weight decreased from day 3 through to day 9, when all animals
either died or were euthanized in moribund condition due to signs
of severe clinical infection and/or significant weight loss (Fig. 4B).
Protective efficacy of H5 vaccine in ferrets
The HA/c-di-GMP vaccine was further evaluated in a ferret
model of influenza infection. In this study, ferrets were vacci-
nated IN twice 14 day apart with 45 mg HA vaccine with or
without 50 mg c-di-GMP or with PBS alone (control), mimick-
ing a shorter vaccination schedule, which could be appropriate in
a pandemic scenario.
Serum samples were collected 12 days after each vaccination
and assayed for HI antibody against A/Indonesia/05/2005 using
horse erythrocytes. No serum antibody responses were detected
after the first or the second vaccination in any of the ferrets
(results not shown).
The ferrets were challenged IN 14 days after the second
vaccine dose with A/Indonesia/05/2005 live virus. Three days
post-viral challenge, 5 ferrets per group were sacrificed and
lung, nasal turbinate, brain, olfactory bulb, spleen and nasal
wash samples were collected. The mean titers of virus recov-
ered from the control animals were higher compared to the
vaccinated animals for all tissues, although the differences
were not statistically significant (Fig. 5). Lower viral titers
were recovered in the nasal turbinates from the animals given
the adjuvanted vaccine than in the animals that had received
HA alone or PBS. For both the vaccinated and control ferrets,
lower virus titers were recovered systemically (brain, olfactory
bulb and the spleen) than in the respiratory tract recovered
from lungs and nasal turbinates.
The survival rates of ferrets, excluding animals sacrificed on day
3 post-challenge are shown in Table 1. All ferrets vaccinated with
the c-di-GMP adjuvanted vaccine survived the viral challenge,
whereas 2 out of 7 animals vaccinated with the non-adjuvanted
vaccine succumbed to infection. In the control group, 4 out of 8
ferrets survived. The difference in survival rates between the con-
trol and the adjuvanted vaccine groups was marginal (p D 0.077).
The body weight of the ferrets was monitored for 14 days post-
viral challenge. The greatest weight loss was observed in control ani-
mals whereas ferrets given the adjuvanted vaccine showed the least
amount of weight loss over the 2-week period (Fig. 6A). Of the ani-
mals that lost weight and survived, half had regained weight by day
14. Excluding the animals sacrificed on day 3, 4 out of 7 animals in
each of the vaccinated groups and all of the control animals lost
5% weight after challenge (Table 1). The maximummean weight
loss was observed in the control group and similar weight losses
were observed in the 2 vaccinated groups (Table 1). Three animals
in the vaccine alone and 2 ferrets in the adjuvanted vaccine group
experienced a serious weight loss (10%), whereas the majority of
the controls (6/8) had this level of weight loss (Table 1).
Figure 5. Virus recovery from the respiratory tract and systemic organs
of vaccinated ferrets after challenge with A/Indonesia/05/2005 (H5N1)
virus. Ferrets were vaccinated with 2 doses of the plant-derived vaccine
(45 mg HA) adjuvanted with c-di-GMP (50 mg), non-adjuvanted vaccine
or PBS (control) 14 days apart by the intranasal route. The ferrets were
then challenged at 14 days after the second vaccine dose with the A/
Indonesia/05/2005 (H5N1) live virus by the intranasal route. On day 3
post-challenge, 5 ferrets from each group were sacriﬁced and lung, nasal
turbinate (NT), brain, olfactory bulb, spleen and nasal wash samples
were collected. Tissue samples were homogenized and the clariﬁed
homogenates and nasal washes were assayed for the presence of A/
Indonesia/05/2005 virus by titration on MDCK cells.
Table 1. Survival rates, temperature rise and weight loss in vaccinated and control ferrets after the A/Indonesia/05/2005 (H5N1) virus challenge. Ferrets were
vaccinated with 2 doses of c-di-GMP adjuvanted plant-derived vaccine, vaccine alone and PBS (control) 14 days apart by the intranasal route. The ferrets
were then challenged 14 days after the second vaccine dose with the A/Indonesia/05/2005 (H5N1) live virus by the intranasal route. On day 14 post-chal-
lenge, the surviving animals were exsanguinated under terminal anesthesia
Vaccine Survival* (%)
No. animals temperature
rise >1C
Mean temperature
rise day 2 (C)
Mean temperature
rise day 3 (C)
Weight
loss 5%*
Weight
loss 10%*
45 mg HA 5/7 (71%) 9/12 0.8 1.3 4/7 3/7
45 mg HA C 50 mg c-di-GMP 7/7 (100%) 10/12 0.9 0.9 4/7 2/7
PBS (controls) 4/8 (50%) 13/13 1.7 1.6 8/8 6/8
* Excluding the animals sacriﬁced on day 3 for post-challenge virus recovery (Fig. 5).
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Following viral challenge of ferrets, changes in body tempera-
ture were monitored daily for 14 days (Fig. 6B). All the control
animals (13/13) and 9/12 and 10/12 vaccinated animals in the
vaccine alone or adjuvanted vaccine groups, respectively, devel-
oped fever (temperature rise >1C) following viral challenge
(Table 1). The maximum mean temperature rises were recorded
at 2 or 3 days post vaccination. The temperature remained stable
in the control and adjuvanted vaccine animals between days 2
and 3 post-challenge, whereas an increase in temperature was
recorded in the vaccine alone group from 0.8 to 1.3C.
Discussion
Since 2003, over 700 confirmed human cases of avian influ-
enza A(H5N1) have been reported to the World Health Organi-
zation with a case fatality rate of approximately 60%.1 With its
high virulence, avian influenza viruses pose a threat to global
public health, but a lack of sustained transmission between
humans has prevented more widespread outbreaks. However,
recent studies have discovered determinants of sustained airborne
transmission of H5N1 viruses in the ferret model.2,4 Ferrets are a
natural host of influenza and represent a well-established model
for influenza research (for a review see ref.14), although it is not
clear whether mutations that led to transmissibility in ferrets will
mediate sustained human-to-human transmission.2 However, it
is now clear that H5N1 viruses can transmit between mammals
and may continue to evolve becoming transmissible in humans,
resulting in a pandemic in the global na€ıve population.
The 2009 H1N1 pandemic clearly demonstrated that we do
not have the capacity to produce enough vaccine doses in a timely
manner to meet the global requirements during a pandemic. In
addition, in the event of an avian influenza pandemic, traditional
use of embryonated hens’ eggs for vaccine production is not a via-
ble option.15 Therefore, the development of new manufacturing
platforms, novel adjuvants and dose-sparing strategies is a prior-
ity. Some of the alternative influenza vaccines being explored
include DNA vaccines, reverse genetics engineered vaccines and
cell-based vaccines using either Vero or MDCK cells.16 We have
previously described a transient plant-based expression system for
producing HA antigens as a low cost and time efficient alternative
to more traditional vaccine manufacturing methods.17 As with
most candidate H5N1 mucosal vaccines, the plant-derived vac-
cines require an effective adjuvant to enhance the immunogenic-
ity and maximise the number of doses obtained from each
production batch.5,18 Here, IN administration of a plant-derived
H5 vaccine in combination with the novel adjuvant c-di-GMP
showed great promise in the mouse and ferret models, protecting
animals from morbidity and mortality associated with the highly
pathogenic avian influenza virus challenge. Furthermore, vaccina-
tion reduced febrile responses, severe weight loss and prevented
the systemic spread of the virus. The immunogenicity results
described in this study for the plant-derived vaccine are compara-
ble to those reported by Shoji et al.,19 although relatively higher
antigen doses (90 and 45 mg HA) and a different adjuvant (Quil
A) were used in their study and importantly, the animals were
immunized subcutaneously. To our knowledge, the current study
is the first showing protective efficacy of a c-di-GMP-adjuvanted,
plant-derived influenza vaccine in mice and ferrets after mucosal
(IN) vaccination. The development of a vaccine/adjuvant formu-
lation that elicits effective mucosal immune responses will be
beneficial in preventing infection and replication at the site of
influenza virus entry (respiratory tract). Furthermore, a mucosal
vaccine may reduce viral shedding and horizontal transmission to
susceptible hosts. In addition, the needle-free self-administration
of mucosal vaccines and associated easier logistics may improve
public compliance, leading to improved immunization coverage.
We have also studied the humoral responses induced by IN
vaccination with the plant-derived HA/c-di-GMP influenza vac-
cine and found that high levels of serum IgG and IgA were
induced in mice after 2 vaccine doses. The increased serum IgA
response may indicate the mucosal origin of these antibodies and
activation of mucosal IgA B lymphocytes.20 In addition, serum
HI antibody was observed in mice after immunization with high
vaccine doses (15 mg and 5 mg of HA). In contrast, IN vaccina-
tion failed to induce a serum HI antibody response in ferrets.
These results differ from those previous reported by Shoji et al.19
Figure 6. Percentage weight loss (A) and changes in body temperature
(B) in vaccinated and control ferrets following challenge with the A/Indo-
nesia/05/2005 (H5N1) virus. Ferrets were vaccinated with 2 doses of 50
mg c-di-GMP adjuvanted vaccine (45 mg HA C c-di-GMP), vaccine alone
(45 mg HA) and PBS (control) 14 days apart by the intranasal route. The
ferrets were then challenged 14 days after the second vaccine dose with
the A/Indonesia/05/2005 (H5N1) live virus by the intranasal route. Ferrets
were monitored daily for 14 days following viral challenge for body
weight and temperature.
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where subcutaneous vaccination with a high dose of a plant-
derived influenza vaccine (90 mg HA, Quil A adjuvanted)
induced a strong serum HI antibody response. Therefore, it will
be interesting to study whether the route of administration or the
adjuvant used determined the serum HI antibody response in fer-
rets. Despite the lack of serum HI antibody responses, all ferrets
in the adjuvanted vaccine group and 80% of mice that received
the 1.5 mg HA vaccine survived the lethal virus challenge. In
fact, the lack of correlation between circulating HI antibody titers
and protective efficacy has been noted previously in ferrets
immunized with pandemic avian influenza vaccines.21,22 Low
serum antibody responses are also a major concern in human
clinical trials of pandemic influenza vaccines (for a review see
ref.23). However, low HI antibody titers may not reflect the true
protective potential of these vaccines as other factors, especially
priming of a cellular immune response and associated cytokine
production, may play a significant role in providing clinical pro-
tection. We have recently shown that IN administration of the
plant-derived HA/cd-i-GMP vaccine induced strong humoral
and cellular immune responses, including a balanced Th1/Th2
cytokine and antibody responses and high frequencies of multi-
functional Th1 CD4C T cells.11 Taken together, our findings
suggest that an effective cellular response may at least in part
explain the high levels of protection observed in ferrets despite
the low titers of serum HI antibodies.
Several pre-clinical studies have convincingly shown the
potent immunostimulatory properties of c-di-GMP when used
as a mucosal adjuvant (for a review see ref.8). The mechanism by
which c-di-GMP stimulates a host immune response is now
being investigated and the transmembrane protein stimulator of
interferon genes (STING) has been shown to function as a sensor
for c-di-GMP and other cyclic dinucleotides (CDNs).24 A pro-
posed mechanism for c-di-GMPs adjuvant properties is that
STING ligation increases the production of type I interferons,25
which in turn drives the adaptive immune response. Parvatiyar
et al.26 showed that cellular DEAD (aspartate-glutamate-alanine-
aspartate)-box helicase DDX41 operates ‘upstream’ of STING to
sense c-di-GMP and other CDNs and is responsible for activat-
ing the STING-dependent pathway that activates the interferon
response. Interestingly, recent studies suggested that STING-
dependent, but IRF3-independent, stimulation of NF-kB signal-
ing leading to TNF-a production is critical for the adjuvant
activity of c-di-GMP.27
The protective efficacy of the plant derived H5 vaccine was fur-
ther examined by evaluating the viral load in the respiratory tract
and systemic organs following immunization and virus challenge.
In both ferrets and humans, highly pathogenic H5N1 viruses
often target the lower respiratory tract (LRT), especially lungs,
mainly due to the presence of a2-3-linked sialic acid receptors
and high viral loads in the LRT are often associated with clinical
signs of severe H5N1 infections.28 In our mouse model, the
reduced viral load in the lung tissue samples on days 3 and 5 post-
challenge indicate that administration of the adjuvanted vaccine
may have reduced the spread of the virus to the lungs. These find-
ings were confirmed in the larger ferret model, where administra-
tion of the adjuvanted vaccine reduced the viral load in the
respiratory tract, and importantly, limited systemic virus spread to
the olfactory bulb, brain and spleen, which may have played a sig-
nificant role in protecting the animals from the lethal H5N1 virus
challenge.29 Earlier studies have reported a strong epidemiological
association between IN vaccination and facial nerve paralysis
(Bell’s palsy) and this was attributed to the use of E. coli LT as an
adjuvant.6,7 However, there is no evidence to suggest that IN vac-
cination with c-di-GMP can cause Bell’s palsy.
In conclusion, we have shown here for the first time that IN
administration of a plant-derived influenza vaccine provide pro-
tection against highly pathogenic avian influenza virus challenge,
making it a promising candidate for a future development as an
intransal influenza vaccine. The protective response was achieved
despite low antibody titers, suggesting that HI titers alone are not
a correlate of protection for a H5 vaccine candidate and that fur-
ther pre-clinical and human studies are needed to determine
these correlates.
Materials and Methods
Virus strains and vaccine preparation
Virus strain
The highly pathogenic A/Indonesia/05/2005 (H5N1) virus
was received from the Centers for Disease Control and Preven-
tion (Atlanta, GA, USA) or Queen Mary Hospital, Hong Kong
and propagated in embryonated hens’ eggs. The allantoic fluid
was aliquoted and stored at ¡70C for use in challenge
experiments.
Vaccine preparation
The recombinant vaccine was expressed in tobacco plants by
agrobacterium gene transfer as described previously.19,30 Briefly,
amino acids 17-532 of the HA gene of the A/Indonesia/05/2005
(H5N1) virus were cloned into a plasmid vector. This vector,
together with a helper plasmid, was transformed into Agrobacte-
rium tumefaciens. The transformed bacteria were cultured over-
night and subsequently vacuum infiltrated into 6-week-old
Nicotiana benthamiana plants. After seven days, leaves were har-
vested and homogenized, the extracts were clarified by centrifuga-
tion, and the HA protein was purified by immobilized metal
affinity chromatography and anion exchange chromatography.
Adjuvant preparation
The c-di-GMP adjuvant was produced as previously described
at Helmholtz Center for Infection Research, Germany.9,31 The
plant-derived vaccine was mixed with the adjuvant immediately
prior to vaccination.
Immunogenicity and protective efficacy in mice
The mouse immunogenicity study was conducted by
Fraunhofer USA Center for Molecular Biotechnology (FhCMB)
at the University of Delaware’s Office of Laboratory Animal
Medicine (Newark, DE, USA). The animal use protocol was
approved by the University of Delaware Institutional Animal
Care and Use Committee (IACUC). The mouse challenge study
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was conducted at Southern Research Institute’s laboratories in
Birmingham, AL, USA that are fully accredited by the Associate
for the Assessment and Accreditation of Laboratory Animal
Care, International (AAALAC). Approval for these studies was
given by the Institutional Animal Care and Use Committee
(IACUC) at Southern Research Institute.
Immunogenicity in mice
Groups of 6-week-old BALB/c mice (Harlan Laboratories,
Indianapolis, IN), 6 mice per group, were immunized IN with
plant-derived vaccine in the presence or absence of 5 mg of c-di-
GMP at 3-week interval on study days 0 and 21. Three different
doses of the vaccine were tested: 15, 5, and 1.5 mg HA. Animals
in the negative control group received PBS plus 5 mg of c-di-
GMP. Serum samples were collected prior to each immunization
and 1, 2, and 3 weeks after the last immunization corresponding
to study days 28, 35, and 42, respectively. Serum IgG, IgA anti-
body titers were determined.
Viral challenge study in mice
BALB/c mice (7-11 week old females from Charles River Lab-
oratories, Kingston, NY) were randomized into 4 groups (16/
mice per group). For IN administration of the vaccine, mice
were anesthetized with Isoflurane to effect and administered
10 mL containing 15 mg, 5 mg, or 1.5 mg of HA in combination
with 5 mg of cdi-GMP IN on study days 0 and 21. Control mice
received 5 mg of cdi-GMP plus PBS on days 0 and 21. On day
42 all mice were anesthetized by intraperitoneal administration
of Ketamine/Xylazine (50 mg/kg Ketamine and 5 mg/kg Xyla-
zine), then challenged IN with A/Indonesia/05/2005 (H5N1)
virus (90 ml, added in a drop wise manner, 102.23 EID50/mL). A
Bair Hugger warm air unit was used to keep animals warm dur-
ing recovery from anesthesia. Body temperatures and weight
were recorded on days 0, 7, 14, 21, 28, 35, 38 and 42 pre-chal-
lenge, then daily post-challenge from day 43 to 56. For pre-vacci-
nation blood collection (day ¡1), mice were anesthetized with
CO2/O2 inhalation and approximately 100 ml of blood from
each mouse was collected from the retro-orbital sinus. On days
20, 32, and 41, approximately 100 ml of blood was collected via
the submandibular route from each non-anesthetized mouse and
serum stored at ¡70C. On days 45 and 47 (3 and 5 days post
challenge), 3 mice from each group were sacrificed by CO2 inha-
lation. The nasal turbinates and lungs were collected, snap frozen
(dry ice) and stored (¡80 § 10C) until evaluation for viral
load in Mardin Darby canine kidney (MDCK) cells. All remain-
ing animals were sacrificed on day 56 by CO2 inhalation.
Vaccination and viral challenge of ferrets
All procedures in the ferret challenge study were carried out
according the UK Home Office License regulations and by indi-
viduals with appropriate personal Home Office Licenses. The
study was approved by the local ethics committee.
Adult male ferrets (Mustela putorius furo, accredited supplier,
UK) at 7-9 months of age were randomly assigned to one of 3
study groups. Ferrets were housed in open pens after vaccination
and then transferred to individual cages prior to challenge.
Animals were fed twice daily with ferret breeding and mainte-
nance diet. All ferrets were seronegative as determined by HI
assays (HI titers < 10) to the H5N1 virus and currently circulat-
ing H3, H1 and B influenza strains.
Animals were sedated with 0.2 mL/kg of Ketamine/Xylazine
before IN immunisation with 2 doses of vaccine 14 days apart
containing 45 mg of HA in PBS alone (n D 12) or with 50 mg
cdi-GMP (n D 12). Control animals received PBS alone (n D
13). Animals were bled from the jugular vein pre vaccination and
12 days after each immunisation and at the time of sacrifice.
Serum and samples were stored at ¡70C until testing in the
serological assays.
Fourteen days after the second immunisation, animals were
sedated with 0.2 mL/kg of Ketamine/Xylazine and challenged by
administering A/Indonesia/05/2005 live virus (106 EID50 in
0.4 mL PBS/BSA) by the IN route. From four days prior to chal-
lenge through 14 days post-challenge, all animals were moni-
tored for fever, weight change and signs of clinical disease
starting. Three days post-challenge, 5 animals from each group
were sacrificed and the lung, nasal turbinate, brain, olfactory
bulb, spleen and nasal washes were collected. The remaining ani-
mals were observed for clinical signs of disease until 14 days post
challenge, when surviving animals were exsanguinated under ter-
minal anesthesia. Animals whose condition exceeded the moder-
ate severity limit of the study were exsanguinated under terminal
anesthesia. All the challenge studies were conducted under
enhanced BSL-3 conditions.
Virus recovery from nasal washings and tissue samples from mice
and ferrets
In the mouse study, lung and nasal turbinate tissues collected
on days 45 and 47 (3 and 5 days post challenge) were thawed
and washed with 1% penicillin-streptomycin in PBS. Lung tis-
sues were homogenized 1:10 (w:v) and nasal turbinates were
diluted at 1:100 (w:v) in homogenization solution (DMEM with
1% penicillin and streptomycin, and 1% L-glutamine) and ana-
lyzed for replication in MDCK cells. Samples were placed on wet
ice or refrigerated for up to 8 hours prior to analysis.
Immediately after collection, ferret tissues were weighed and
homogenized in L15 medium containing penicillin (1000 IU)
and streptomycin (100 mg/ml). Homogenates were clarified by
centrifugation and aliquots frozen at ¡70C. Nasal washings,
and clarified tissue homogenates were inoculated undiluted or
diluted (10¡1–10¡8) into MDCK cells in 96 well tissue culture
plates and plates were incubated at 35C for 3 days. Aliquots of
medium from each well were transferred to wells of U-well
microtiter plates and the presence of replicating virus detected
using 0.7% turkey erythrocytes. Virus titers were calculated by
the method of Spearman-Karber.32 The limit of detection for the
mouse assay was 102.5 TCID50/mL for nasal turbinates and 10
1.5
TCID50/mL for lung tissue samples. The limit of detection for
the ferret samples was 101.3/g or 101.56/mL.
Enzyme-linked immunosorbent assay (ELISA)
The influenza-specific murine serum IgG and IgA antibodies
were quantified by ELISA assay, as previously described.33,34
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Briefly ELISA plates were coated with inactivated A/Indonesia/
05/2005 virus and samples of serum were tested in a series of 2-
or 4-fold dilutions. Antigen-specific IgG and IgA were detected
using horseradish peroxidase-conjugated goat anti-mouse IgG or
IgA antibody (Jackson Immunoresearch Laboratories Inc., West
Grove, PA, USA), respectively. Endpoint titers were determined
as reciprocal serum dilutions that gave mean optical density val-
ues 3 times greater than those from pre-immune sera at a 1:100
or 1:50 dilution for IgG and IgA, respectively.
HI assay
Sera were treated to remove non-specific inhibitors by 1/4
dilution in receptor destroying enzyme (Seiken, Japan) and incu-
bation for 18 hours at 37C followed by 45 minute incubation
at 56C and tested by a modified HI assay.35,36 The HI assay was
performed by a standard micro-titer method using 2-fold serial
dilution of sera in 25 ml volumes, 4 haemagglutinating units of
IBCDC-RG2 and 1% horse erythrocytes. Each serum sample
was tested at least twice and the results reported as the geometric
mean of the readings. The serum HI titer was expressed as the
reciprocal of the highest dilution at which haemagglutination
was inhibited and titers less than 10 were assigned an arbitrary
value of 5 for calculation purposes.
Statistical analyses
Non-parametric Kruskall-Wallis multiple comparisons test
was used to analyze differences between the groups using Graph-
Pad Prism version 6 for Mac (GraphPad Software, La Jolla, CA,
USA) and a P value < 0.05 was considered to be statistically
significant.
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